Hoffmann-la Roche

This study followed over 1700 people with multiple sclerosis (MS) who were prescribed ocrelizumab as part of their normal care. Researchers tracked changes in symptoms like fatigue, walking, hand function, and thinking, as well as side effects. The goal was to see how well the dr…

This study looked at how well and how safely the drug ocrelizumab works over a longer period for people with multiple sclerosis (MS). It included over 1,000 participants who had already taken ocrelizumab in earlier Roche-sponsored studies. Researchers tracked disability progressi…

This study looked at the long-term safety of faricimab, a medicine injected into the eye, for people with wet age-related macular degeneration (a leading cause of vision loss). Over 1000 adults who had already completed earlier faricimab studies took part. The main goal was to tr…

This study observed 178 Chinese patients with advanced HER2-positive breast cancer who received the drug T-DM1 after earlier treatments failed. Researchers tracked side effects and how long the drug kept the cancer from growing in real-world settings. The goal was to confirm that…

This study tested several immunotherapy-based drug combinations in 144 people with advanced hormone receptor-positive, HER2-negative breast cancer that had worsened after initial treatment with CDK4/6 inhibitors. Participants received either standard hormone therapy (fulvestrant)…

This study tested a drug called alogabat in 48 children aged 5-17 with Angelman syndrome caused by a specific gene deletion. The goal was to see how the drug moves through the body and if it is safe, while also checking for early signs it might help control symptoms. The study la…

This study tested an experimental drug called vamikibart, given as an eye injection, for people with uveitic macular edema — swelling in the back of the eye caused by inflammation. The goal was to see if it improves vision and reduces swelling better than a sham (fake) procedure.…

This study tested an experimental drug called vamikibart (RO7200220) given as an eye injection for people with diabetic macular edema, a condition where diabetes causes swelling in the back of the eye and blurs vision. About 394 participants received either the new drug or an act…

This study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab) in 172 people with advanced or recurrent PD-L1-positive cervical cancer. The goal was to see if the combination could shrink tumors better than atezolizumab alone. The study found that some …

This study tested a small, refillable implant placed in the eye that continuously releases the drug ranibizumab to control diabetic retinopathy. It involved 174 adults with moderate-to-severe diabetic retinopathy but no swelling in the center of the retina. The main goal was to s…

This study tested an experimental drug called vamikibart, given as an eye injection, for people with uveitic macular edema—a condition where the back of the eye swells due to inflammation. The trial involved 256 adults with active or inactive eye inflammation. The main goal was t…

This study tested a medicine called emicizumab in 73 people with mild or moderate hemophilia A who do not have inhibitors. The goal was to see if it safely reduces bleeding episodes. Participants received regular injections, and researchers tracked how many bleeds occurred. The r…

This study tested two new experimental drugs (lomvastomig and tobemstomig) against the standard treatment nivolumab in 190 people with advanced or metastatic esophageal squamous cell carcinoma that had stopped responding to prior chemotherapy. The goal was to see if the new drugs…

This study tested whether adding polatuzumab vedotin to standard chemotherapy (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 270 adults took part. The goal was to see if the combination improves survival and controls the cancer bet…

This study tested whether adding a new drug (RO7200220) to the standard treatment (ranibizumab) works better than standard treatment alone for people with diabetic macular edema, a condition that causes vision loss. About 187 participants received injections into the eye over 76 …

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with a fast-returning, advanced form of triple-negative breast cancer live longer. About 595 participants whose cancer had spread or couldn't be surgically removed were rand…

This study tested whether adding tiragolumab to atezolizumab (both immunotherapy drugs) works better than atezolizumab alone in people with a certain type of lung cancer (PD-L1 positive non-small cell lung cancer) who had surgery and chemotherapy. The trial enrolled 56 adults wit…

This study tested a new drug combination (tiragolumab plus atezolizumab and chemotherapy) against a standard treatment (pembrolizumab plus chemotherapy) in 542 people with advanced non-squamous lung cancer who had not received prior treatment. The goal was to see if the new combo…

This study looked at the long-term safety of the drug tocilizumab (RoActemra/Actemra) in children with a type of arthritis called polyarticular-course juvenile idiopathic arthritis. Seven children who had already finished a main study received the drug every 4 weeks for up to 2 y…

This study tested whether adding tiragolumab to the standard immunotherapy atezolizumab helps people with advanced non-small cell lung cancer (NSCLC) live longer without their cancer growing. About 620 adults with high PD-L1 levels who had not received prior treatment were random…

This study tested a monthly injection called Mircera in 75 adults with chronic kidney disease and anemia who were not yet on dialysis. The goal was to see if the drug could safely raise and maintain healthy red blood cell levels. Participants received shots once a month for up to…

This study tested different combinations of immunotherapy drugs given before surgery for liver cancer that can be removed. The goal was to see if these treatments could shrink or eliminate the tumor before the operation. 62 participants took part, and the study is now complete.

This study tested a new drug called glofitamab combined with standard chemotherapy (R-ICE) in 43 adults with diffuse large B-cell lymphoma that returned after initial treatment. Participants were eligible for a stem cell transplant or CAR-T therapy. The goal was to see if the com…

This study tested several combinations of immunotherapy drugs in 341 people with pancreatic cancer that had spread to other parts of the body. Participants were split into two groups: those who had not yet received any treatment for their advanced cancer, and those who had alread…

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 152 people with advanced liver cancer that could not be removed by surgery and had not been treated with systemic therapy before. The main goal was to check safety, especially serious bleeding side eff…

This study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants were grouped by prior treatment history and received either a comb…

This study tested new combinations of drugs in 281 people with chronic hepatitis B who had stable liver function. Participants took the study drugs for up to 48 weeks and were monitored for safety and whether they lost the hepatitis B surface antigen (a key sign of infection cont…

This study tested whether adding two immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy helps people with advanced esophageal cancer that cannot be removed by surgery. About 461 participants received either the drug combo plus chemo or a placebo plus chem…

This study tested a new way to give two cancer drugs together as a single infusion. The drugs, tiragolumab and atezolizumab, aim to help the immune system fight tumors. 64 adults with advanced solid tumors that had not responded to other treatments took part. The main goal was to…

This study tested a new combination of two drugs (obinutuzumab and venetoclax) against a standard combination (obinutuzumab and chlorambucil) in 445 people with untreated chronic lymphocytic leukemia (CLL) who also had other medical conditions. The goal was to see which combinati…

This study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy could help people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for their extensi…

This study tested whether adding a second immunotherapy drug (tiragolumab) to a standard one (atezolizumab) helps shrink tumors in people with advanced head and neck cancer that has spread or come back. 123 adults whose tumors had a specific protein (PD-L1) took part. The main go…

This study looked at a new way to give two breast cancer drugs (pertuzumab and trastuzumab) as a single shot under the skin instead of through an IV drip. It involved 200 Chinese patients with HER2-positive early breast cancer. The goal was to see if the shot works as well as the…

This study looked at 322 adults with moderate to severe rheumatoid arthritis who were starting treatment with tocilizumab (Actemra/RoActemra). Researchers tracked their disease activity for 12 months to see how well the drug worked in real-world clinics, not just in controlled tr…

This early-phase study tested a new drug called eciskafusp alfa, alone or with another immunotherapy (atezolizumab), in 189 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose. Researcher…

This study tested a combination of two drugs, atezolizumab and cabozantinib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that had worsened after prior treatments. The goal was to see if the combination helped people live longer. …

This study tested several drug combinations in 12 people with advanced head and neck cancer that had not been treated yet. The goal was to see if the drugs could make the tumors disappear before surgery. The study is complete, and results help guide future treatment options.

This study tested the safety and how the body handles risdiplam in 174 adults, children, and infants with spinal muscular atrophy (SMA). Participants had previously received other SMA treatments. The goal was to see if risdiplam is safe and to measure its levels in the blood. Thi…

This study looked at how well MIRCERA works and how safe it is for treating anemia in people with moderate chronic kidney disease (stages 3-4) who are not yet on dialysis. Researchers tracked 144 adults over a year to see if their hemoglobin levels stayed in a healthy range. The …

This study tested a drug called TRO19622 in 22 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants took either the drug or a placebo for one month to see if it safely lowered liver enzymes. The goal was to check short-term safety and effe…

This study tested a combination of two targeted drugs, venetoclax and obinutuzumab, against standard chemotherapy (FCR or BR) in 166 fit patients with previously untreated chronic lymphocytic leukemia (CLL) who lacked certain genetic mutations. The goal was to see if the new comb…

This study tested whether using a person's tumor genetic profile to choose treatment (targeted therapy or immunotherapy) works better than standard chemotherapy for cancer of unknown primary site. About 529 adults whose cancer was controlled after initial chemo were randomly assi…

This study tested a new drug called PF-06480605 in 246 adults with moderate to severe ulcerative colitis. Participants received different doses of the drug or a placebo for 12 weeks, then all received the active drug for 40 more weeks. The goal was to see if the drug could help a…

This study tested a medicine called emicizumab in 85 people with hemophilia A, a condition that causes frequent bleeding. Participants received either weekly or monthly injections of emicizumab, or no preventive treatment. The goal was to see if emicizumab could reduce the number…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps people with early-stage non-small cell lung cancer. About 453 participants received either the drug combo or a placebo with chemo, followed by surgery and possibly m…

This study looked at the long-term safety of faricimab, an injected eye medication, in people with diabetic macular edema. Over 1,400 patients who completed earlier studies received personalized treatment intervals. The main goal was to track eye and body side effects over time.

This study tested several immunotherapy drug combinations in 272 people with advanced bladder cancer that had worsened after standard chemotherapy. The goal was to see if these combinations could shrink tumors or slow the disease. Participants could switch to a different combinat…

This study tested whether a shot under the skin (subcutaneous) of the immunotherapy drug atezolizumab works as well as the standard IV drip for people with advanced non-small cell lung cancer. About 438 patients who had already tried chemotherapy took part. The goal was to see if…

This large study tested whether adding pertuzumab to standard chemotherapy and trastuzumab helps prevent breast cancer from returning after surgery. Over 4,800 people with HER2-positive breast cancer took part. The results showed that the three-drug combination improved the chanc…

This study tested a new drug called RO7247669 in 93 people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if the drug could shrink tumors or slow the disease. Participants received one of two dose levels to find the best dose for fu…

This study tested the safety of combining the immunotherapy drug atezolizumab with the chemotherapy nab-paclitaxel in 184 people with advanced triple-negative breast cancer that had a specific protein (PD-L1). Participants had not received chemotherapy for their advanced disease.…

This study tested whether a combination of two immunotherapy drugs (atezolizumab and tiragolumab) works better than the standard drug (durvalumab) for people with stage III lung cancer that cannot be removed by surgery. Participants had already received chemotherapy and radiation…

This early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goal was to find the safest dose and check for side effects. Researchers also looked for s…

This early-phase study tested a new drug called forimtamig in 225 people with multiple myeloma that returned or didn't respond to standard treatments. The goal was to check the drug's safety and find the right dose. Participants had no other good treatment options left.

This study tested a medicine called crovalimab to see if it can prevent painful vaso-occlusive episodes (VOEs) in people with sickle cell disease. 95 participants received either crovalimab or a placebo alongside their usual treatments. The goal was to reduce the number of VOEs r…

This study looked at whether people with HER2-positive breast cancer prefer getting their medication at home versus in the hospital. About 346 participants received a combination of two drugs (pertuzumab and trastuzumab) as a shot under the skin. The main goal was to see which se…

This study tested a single dose of baloxavir marboxil against a 5-day course of oseltamivir in 100 Chinese children aged 1 to 12 with flu symptoms. The main goal was to check safety and how quickly symptoms like fever and cough improved. Results help doctors understand if a one-t…

This study tested whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a quick shot under the skin (subcutaneous) or as a longer IV drip into a vein. About 179 patients tried both methods and reported which they liked better. The goal was to see …

This study looked at how much of the multiple sclerosis (MS) drug ocrelizumab gets into breastmilk and whether it affects babies' immune cells. Twenty-six breastfeeding women with MS or a first MS-like episode took part. Researchers measured drug levels in breastmilk and checked …

This study measured the thickness of the conjunctiva and Tenon's capsule (parts of the eye) in 736 people with neovascular age-related macular degeneration or diabetic macular edema, and in healthy volunteers of similar age. Researchers used a special imaging device (SD-OCT) to t…

This study looked at whether using a blood test (liquid biopsy) early in the diagnosis process could help doctors decide on cancer treatment faster for people with advanced lung or stomach/bowel cancer. About 463 people took part. The blood test was compared to the usual method o…

This study tested tumor samples from 470 people with solid tumors to look for specific biomarkers. The goal was to see if those biomarkers could make them eligible for other Roche clinical trials. No treatment was given in this study—it was purely a screening step to help match p…

This study looked at 70 pregnant women with multiple sclerosis or clinically isolated syndrome who took the drug ocrelizumab before or during early pregnancy. Researchers measured B cell levels in their babies to see if the drug crossed the placenta. The goal was to gather safety…